PRIMARA: a prospective descriptive observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice

Schwartz, Peter J.; Body, Jean‐Jacques; Čáp, Ján; Hofbauer, Lorenz C.; Farouk, Mourad; Gessl, Alois; Kuhn, M.; Marcocci, Claudio; Mattin, Caroline; Munoz, Torres Manuel; Payer, Juraj; van, de Ven Annenienke; Yavropoulou, Maria P; Selby, Peter

doi:10.1530/endoabs.32.p982

Cited by 11 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Recently, cinacalcet, a calcimimetic agent, has been proved in a prospective observational study to be effective in lowering serum calcium levels in people with sporadic and familial primary hyperparathyroidism, but it has no effects on other features of primary hyperparathyroidism-that is, bone mineral density and hypercalciuria. 25 with primary hyperparathyroidism with specific indications. The EMA panel stated that cinacalcet can be an option in those where parathyroidectomy is indicated based on serum calcium levels but for whom surgery is otherwise "not clinically appropriate or contraindicated."…”

Section: Mild Hypercalcaemiamentioning

confidence: 99%

“…Admission to hospital is required for people with severe hypercalcaemia (>3.5 mmol/L); emergency treatment includes aggressive intravenous hydration with 3-4 litres of 0.9% saline daily, or 1-2 litre bolus of 0.9% saline, followed by 200-250 mL saline hourly. 25 The rationale underlying hydration is that people with hypercalcaemia are often severely dehydrated, mainly because of nephrogenic diabetes insipidus due to hypercalcaemia and reduced water intake. The latter results from anorexia, nausea, and vomiting induced by the hypercalcaemia itself as well as the causative disease, such as neoplasia.…”

Section: Severe Hypercalcaemiamentioning

confidence: 99%

See 1 more Smart Citation

The diagnosis and management of hypercalcaemia

Minisola

Pepe

Piemonte

et al. 2015

BMJ

181

150

View full text Add to dashboard Cite

Hypercalcaemia is a common finding in the setting of primary care, 1 as well as in emergency departments 2 and patients admitted to hospital. 3 Primary hyperparathyroidism and malignancy are the two most common causes of increased serum calcium levels, together accounting for about 90% of all cases. 4 The remaining 10% represent an important figure, and thus the need to consider other disorders in the evaluation of patients with hypercalcaemia. This review aims to give an overview of the diagnosis and clinical management of hypercalcaemia for non-specialist clinicians and health professionals.

show abstract

Section: Mild Hypercalcaemiamentioning

confidence: 99%

Section: Severe Hypercalcaemiamentioning

confidence: 99%

The diagnosis and management of hypercalcaemia

Minisola

Pepe

Piemonte

et al. 2015

BMJ

181

150

View full text Add to dashboard Cite

show abstract

“…Long-term up to 5 years administration of cinacalcet is associated with a sustained control of hypercalcemia and PTH levels. However, changes in bone mineral density could not be detected [1][2][3][4][5][6][7][8][9][10].…”

Section: English Versionmentioning

confidence: 87%

“…L'administration du cinacalcet à long terme jusqu'à 5 ans s'associe à un contrôle durable de l'hypercalcémie et des taux de PTH. Toutefois, on ne peut mettre en évidence de changement de la densité minérale osseuse [1][2][3][4][5][6][7][8][9][10].…”

Section: Version Françaiseunclassified

Benefits and place of calcimimetics in the management of primary hyperparathyroidism

Meier

2015

Annales d'Endocrinologie

View full text Add to dashboard Cite

“…Cinacalcet is a calcimimetic agent that activates the calcium sensing receptor (CaSR) on the surface of parathyroid glands. In addition to parathyroid cells, the CaSR is expressed along the nephron as well as in other tissues and is the regulator of PTH synthesis and secretion [85,86]. By increasing the sensitivity of the CaSR to extracellular calcium it effects a reduction in PTH and therefore a reduction in serum calcium level [87,88].…”

Section: Duration Of Actionmentioning

confidence: 99%

Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature

et al. 2019

View full text Add to dashboard Cite

Hypercalcemia of malignancy is the most common life-threatening metabolic disorder in patients with advanced stage cancers and is a sign of poor prognosis. It usually presents with markedly elevated calcium level and is severely symptomatic. It is associated with hematological malignancies, such as multiple myeloma, non-Hodgkin lymphoma, leukemias and solid cancers, particularly renal and breast carcinomas as well as squamous cell carcinomas of any organ. Several mechanisms have been implicated in the development of hypercalcemia of malignancy amongst them the osteolytic related hypercalcemia, parathyroid hormone-related peptide (PTHrP) mediated hypercalcemia, extrarenal 1,25 dixydroxyvitamin D (calcitriol) mediated hypercalcemia and parathyroid hormone (PTH) related hypercalcemia either ectopic in origin or in patients with parathyroid carcinoma. Clinical history and and physical examination could point towards the correct diagnosis confirmed by the above-mentioned biochemical mediators of hypercalcemia. Early diagnosis and treatment lowering calcium levels in the blood can improve symptoms and the quality of life of these patients and avoid delays for further antitumor therapy.

show abstract

PRIMARA: a prospective descriptive observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice

Cited by 11 publications

References 0 publications

The diagnosis and management of hypercalcaemia

The diagnosis and management of hypercalcaemia

Benefits and place of calcimimetics in the management of primary hyperparathyroidism

Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature

Contact Info

Product

Resources

About